Stay updated on Filgotinib and Lanraplenib in Female CLE Clinical Trial
Sign up to get notified when there's something new on the Filgotinib and Lanraplenib in Female CLE Clinical Trial page.

Latest updates to the Filgotinib and Lanraplenib in Female CLE Clinical Trial page
- Check2 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check31 days agoChange Detected- Revision: v3.5.0 has been added, replacing Revision: v3.4.3.SummaryDifference0.0%

- Check46 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check67 days agoChange DetectedThe page shows a revision update from v3.4.1 to v3.4.2, which is a minor maintenance change. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check75 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1. No visible changes to study content.SummaryDifference0.0%

- Check97 days agoChange DetectedRevision: v3.3.4 replaces v3.3.3 on the page, a non-functional metadata update that does not affect study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Filgotinib and Lanraplenib in Female CLE Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Filgotinib and Lanraplenib in Female CLE Clinical Trial page.